		Commissioner for Patents, Box P United States Patent and Trademark Off Washington, D.C. 202 www.usplu.
U.S. APPLICATION NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/831975	PANZNER	S PANZNER PCT INTERNATIONAL APPLICATION NO.
COLLARD & ROE	ARD	PCT/EP99/09744
ROSLYN, NY 11576 1696		I.A. FILING DATE PRIORITY DATE
		15 NOV 99 17 NOV 98
NOTHICATION OF M		DATE MAILED: 28 JUN 2001
	IISSING REQUIREMENTS UNDE ES DESIGNATED/ELECTED OFF	R 35 U.S.C. 371 IN THE UNITED ICE (DO/FO/US)
1. The following items have been Office as a Designate	n submitted by the applicant or the IB to the Id office (37 CFR 1.494) an Elected Offi	United States Patent and Trademark ice (37 CFR 1.495):
U.S. Basic National		
Copy of the internation of Copy of Article 19 a	of inventors(s). Translation of Article	ernational application into English. e 19 amendments into English.
Priority Document.		
U	liminary Examination Report in English and ses to the International Preliminary Examination	-
the indicated items in paragraph 3	below. The Basic National Fee and the copy priority date to avoid abandonment.	not filed the following indicated items and/or of the international application must be filed onal application.
acceptance under 35 U.S.C. 371:	e furnished within the period set forth below i	·
later than the a	application into English. A processing fee w oppropriate 20 or 30 months from the priority of aslation is defective for the reasons indicated	late.
Translation.		
appropriate 20	providing the translation of the application as or 30 months from the priority date (37 CFR n of the inventors, in compliance with 37 CFI	1.492(f)).
the application	(preferably by the International application nube required if submitted later than the appropr	mber and international filing date). A
	h or declaration does not comply with 37 CFI	R 1.497(a) and (b) for the reasons
d. Surcharge for pro-	e attached PCT/DO/EO/917. viding the oath or declaration later than the ap	propriate 20 or 30 months from the
4. Additional claim fees of \$	7 CFR 1.492(e))as a large entity small entit tt must submit the additional claim fees or car ched PTO-875.	y, including any required multiple dependent icel the additional claims for which fees are
5. Applicant has not submitted PCT/DO/EO/920.	d the required sequence listing pursuant to 37	CFR 1.821-1.825. See attached
MONTHS FROM THE DATE	THE APPLICATION, WHICHEVER IS LA	THS (where 37 CFR 1.495 applies) FROM
The time period set above may be 1.136(a).	e extended by filing a petition and fee for exte	nsion of time under the provisions of 37 CFR
Annexes will be cancelled. A pro	ocessing fee will be required if submitted later s are cancelled since a translation was not pro	d no later than the time period set above or the than 20 or 30 months from the priority date. vided by the appropriate 20 (37 CFR 1.494(d))
Applicant is reminded that any co	mmunication to the United States Patent and	Frademark Office must be mailed to the

address given in the heading and include the U.S. application no. shown above. (37 CFR 1.5)

A copy of this notice MUST be returned with this response.

Enclosed: PCT/DO/EO/917 Notice of Defective Translation Notice of Defective Translation
|X| PCT/DO/EO/920 ___ PTO-875 Barbara A. Campbell Telephone: 703-305-3631 FORM PCT/DO/EO/905 (March 2001)

Commissioner for Patents, Box PCT United States Patent and Trademark Office Washington, D.C. 20231

U.S. APPLICATION NO.	FIRST NAMED APPLICANT		ATTY. DOCKET NO.
09/831975	PANZNER	S	PANZNER PCT
		INTERNATIONAL	APPLICATION NO.
COLLARD & ROE 1077 NORTHERN BOULEVARD		PCT/EP	99/09744
ROSLYN, NY 11576 1696		I.A. FILING DATE	PRIORITY DATE
		15 NOV 99	17 NOV 98
		DATE MAILED:	28 JUN 200

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

Th W re

the nucleotide and/or amino acid sequence disclosure con with the requirements for such a disclosure as set forth in eason(s):	
The application fails to comply with the require	ements of 37 CFR 1.821-1.825.
This application does not contain, a "Sequence	
disclosure on paper copy or compact disc, as A copy of the "Sequence Listing" in computer	
required by 37 CFR 1.821(e).	readable form has been submitted. The
A copy of the "Sequence Listing" in computer content of the computer readable form, howev 37 CFR 1.822 and/or 1.832, as indicated on the Sequence Listing."	er, does not comply with the requirements of
The computer readable form that has been file	d with this application has been found to be
damaged and/or unreadable as indicated on the substitute computer readable form must be sult. The paper copy or compact disc of the "Seque	omitted as required by 37 CFR 1.825(d).
computer readable form of the "Sequence List	
Other:	
An initial or substitute computer readable form An initial or substitute paper copy or compact amendment directing its entry into the specific A statement that the contents of the paper or c are the same and, where applicable, include n 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825 FOR QUESTIONS REGARDING COMPLIANCE WITH	disc of the "Sequence Listing," as well as an ation. ompact disc and the computer readable form o new matter, as required by 37 CFR 5(d).
CALL:	
(703) 308-4216, for Rules interpretation, (703) 308-4212, for CRF submission help,	
(703) 287-0200, for Patentin software help.	
	Barbara A. Campbell
,	Telephone: 703-305-3631